论文部分内容阅读
左乙拉西坦,商品名为开浦兰,系UCB公司全新机制的专利抗癫癎药物。2000年在欧洲、美国同步上市,其结构和作用机制与任何已上市的抗癫癎药物不同,开创了癫癎治疗的新纪元,目前在全球超过66个国家和地区上市。左乙拉西坦已是美国癫癎治疗应用最多的新型抗癫癎药物,占同类产品中超过20%的市场份额。优时比制药公司与《中国临床神经科学》将于2009年联合举办第一届左乙拉西坦优秀论文征集活动。征文经专家评选将颁发左乙拉西坦优秀论文奖。
Levetiracetam, marketed as Kaplan, is a patented anti-epileptic drug developed by the new UCB company. In 2000, the simultaneous listing in Europe and the United States, the structure and mechanism of action and any listed antiepileptic drugs, creating a new era of epilepsy treatment, currently in more than 66 countries and regions in the world. Levetiracetam is the new antiepileptic drug most used in the treatment of epilepsy in the United States, accounting for more than 20% of the market share of similar products. Youbu Biopharmaceutical Company and China Clinical Neuroscience will co-host the first levetiracetam excellent essay solicitation in 2009. The essay will be awarded the Excellent Essay Award for Levetiracetam by the experts.